|
| Disease | Cells analyzed | | Study groups | MN | Year/reference |
| Basal | Posttreatment |
|
| Organ specific autoimmune diseases |
|
| Graves’ disease (GD)
| Ly 2000 cells
| 11
| GD + vit. E, after 131I
| 4.0 ± 3.2
| 10.3 ± 1.7 (7 d)c
13.7 ± 2.3 (21 d)
3.9 ± 2.2 (180 d)
| 2004 [18]
|
Ly 2000 cells | 15 | GD + placebo after 131I | 5.2 ± 1.0 | 12.5 ± 1.6 (7 d)
24.7 ± 3.6 (21 d)c |
2007 [19] |
10
| GD + Ginkgo biloba after 131I
| 8.7 ± 1.8
| 14.3 ± 2.2 (7 d)
12.4 ± 1.9 (21 d)
|
| Ly NA | 25
25 | GD 7 days after 131I
GD 30 days after 131I | NA
NA | 2.4 ± 1.4%
1.9 ± 0.2%a | 2011 [20] |
|
| Diabetes mellitus (DM)
| BM 2000 cells
| 55
23
30
81
| T1DM
T2DM
DM + folic acid
Healthy subjects
| 2.4 ± 1.4b
2.6 ± 1.6
2.5 ± 1.4
1.2 ± 1.2
| 0.7 ± 0.6c (30 d)
| 2007 [21]
|
| Ly 2000 cells | 35
15 | T1DM
Healthy subjects | 1.8 ± 1.2
1.5 ± 0.6 | | 2009 [22] |
|
| Multiple sclerosis (MS)
| Ly 1000 cells
| 23
20
| MS + radiation
Healthy subjects
| 45.3 ± 3.3
27 ± 3.5
| 381 ± 16a
347 ± 13
| 2006 [23]
|
| Ly 1000 cells | 18
18
20 | RRMS + radiation
SPMS + radiation
Healthy subjects + radiation | 14.2 ± 6.1
12.7 ± 4.4
15.2 ± 6.5 | 86.0 ± 15.9a
86.6 ± 22.8a
96.7 ± 19.4a | 2013 [24] |
|
| Vitiligo | Ly 1000 cells | 21
21 | Vitiligo without treatment
Healthy subjects | 0.9 ± 0.6%a
0.6 ± 0.3% | | 2008 [25] |
|
| Psoriasis | Ly 1000 cells | 5
6
5
5 | P + acitretin (oral) alone
P + acitretin + NBUVB
Acitretin + PUVA
Healthy subjects | NA
NA
NA
NA | NS
NS
a
NA | 2013 [26] |
|
| Systemic autoimmune diseases |
|
| Rheumatoid arthritis (RA)
| BM 2000 cells
| 29
50
40
39
| RA without MTX
RA with MTX
RA + MTX + folic acid
Healthy subjects
| 3.5 ± 1.5
3.1 ± 3.1
3.1 ± 2.9
0.8 ± 0.8
| 3.1 ± 2.8
| 2002 [12]
|
| Ly 1000 cells | 12
31
30 | Active RA
Inactive RA
Healthy subjects | 3.3 ± 1.3a
3.2 ± 1.1a
1.9 ± 1.1 | | 2011 [27] |
|
| Systemic lupus erythematosus (SLE)
| Ly 2000 cells
| NA
| SLE without treatment
SLE with CYC
Healthy subjects
| 6.2 ± 2.4
10.1 ± 4.7c
5.5 ± 2.2
| | 1995 [28]
|
Ly 2000 cells
| 15
18
| SLE without treatment
Healthy subjects
| 10.6 ± 3.9%
9.1 ± 4.6%
| | 1999 [4]
|
BM 1000 cells
| 10
10
7
7
43
| SLE before first CYC bolus
SLE 14 days after 1st CYC bolus
SLE before second CYC bolus
SLE 14 after the 2nd CYC bolus
Healthy subjects
| NA
| 1.5 ± 1.6
2.9 ± 2.1
4.5 ± 2.3a
7.0 ± 2.8b
1.3 ± 1.3
| 2000 [13]
|
BM 1000 cells
| 25
24
43
| SLE without CYC
SLE with CYC
Healthy subjects
| 0.9 ± 1.1
1.3 ± 1.2
1.3 ± 1.4
| 3.4 ± 2.2 (14 d)c
| 2004 [29]
|
| BM 1000 cells | 58
58 | SLE patients
Healthy controls |
Median cell counts of MN were significantly higher among SLE patients | 2014 [30] |
|
| Systemic sclerosis (SSc)
| Ly 2000 cells
| 11
5
6
18
| SSc
SSc (ACA+/Scl70−)
SSc (ACA−/Scl70+)
Healthy subjects
| 27.4 ± 19.9b
38.0 ± 24.9b
18.7 ± 9.5b
9.1 ± 4.6
| | 1999 [4]
|
Ly 1000 cells
| 43
13
16
25
| SSc
Idiopathic RP
Secondary RP
Healthy subjects
| 19.1 ± 2.1
23.5 ± 2.7
9.4 ± 2.2
25.9 ± 1.7
| | 2003 [31]
|
| Fibroblasts 1000 | 10
10
9 | SSc (nonaffected skin) + bleomycin
SSc (affected skin) + bleomycin
Healthy subjects + bleomycin | 15.4 ± 13.6
14.0 ± 12.0
4.7 ± 3.3 | 38.5 ± 17.9a
38.0 ± 26.1a
20.5 ± 13.1 | 2010 [32] |
|
| Behçet’s disease (BD)
| BM 1000 cells | 10
6
4
9 | Patients with BD
BD treated with colchicine
BD without colchicines
Healthy subjects | 1.9 ± 0.9
1.7 ± 1.0
2.3 ± 0.5
0.8 ± 0.7 | | 2005 [33] |
Ly 1000 cells
| 30
10
20
20
| Patients with BD
BD without colchicine
BD with colchicine
Healthy subjects
| 3.4 ± 1.1
3.6 ± 1.2a
3.4 ± 1.1a
2.2 ± 0.7
| |
Ly 1000 cells
| 14
16
20
| BD inactive
BD active
Healthy subjects
| 3.1 ± 1.3b
3.2 ± 1.2a
2.2 ± 0.7
| | 2009 [34]
|
| Ly 1000 cells | 18
22
30 | BD negative HLA-B51
BD positive HLA-B51
Healthy subjects | 2.6 ± 0.7c
3.5 ± 0.7c
1.7 ± 0.3 | | 2013 [35] |
|
